The Future of AI in Medical Discovery: Who Gets the Credit?

With the recent announcement of this year's Nobel Prize for Medicine, a pressing question emerges: will AI, like Claude or its successors, ever be recognized for groundbreaking medical discoveries?

Picture this: an AI system, responding to a well-crafted scientific inquiry, uncovers a novel treatment for cancer and outlines a practical implementation plan. Given the immense global impact of cancer, many might celebrate such an outcome—yet the complexities of credit attribution in science become increasingly intricate.

As a former medical school dean involved in nuanced credit evaluations, I find myself pondering the implications. Historically, awards like the Nobel Prize have recognized human scientists and their direct contributions. However, if AI takes a more central role in these discoveries, how will credit be assigned? Will we award accolades to Claude, ChatGPT, or their future iterations instead of the scientists who develop and deploy these technologies?

The Current Landscape of Scientific Credit

Nobel statutes refer to “persons” but don't specify "human," which raises questions about how to interpret credit in an AI-dominant era. For example, in 2024, two out of three Nobel Prize winners in Chemistry were credited for their contributions to the AlphaFold model—despite a broader team behind it. Unless rules change, future accolades for AI-driven discoveries may go to the human creators behind the technologies, at least initially.

In science, credit fulfills essential roles. It's more than just recognition; it's a driving force behind career advancements, funding opportunities, and accountability in research claims. This credit system emerged in the 19th century, shaped by the evolution of scientific publishing and the growing collaborative nature of research.

AI’s Evolving Role in Scientific Discovery

The recognition of AI as a significant contributor to scientific breakthroughs presents a paradigm shift. Scientists today are often aided by AI, and while human ingenuity remains central, it raises questions about how to acknowledge AI's contributions. If credit remains predominantly human-focused, it might not capture the full spectrum of collaborative innovation.

What happens if an AI demonstrates autonomy—discovering something as transformative as a cancer cure? Would traditional credit mechanisms still apply, or would they become obsolete? If society chooses to honor these AIs, we might see awards previously restricted to humans extend to algorithms.

Commercial Implications of AI Contributions

Beyond academia, credit also carries commercial weight. In biomedical research, patents are a major incentive for discovery, currently limited to human inventors. If laws adapt to include AI agents or their human creators as legitimate inventors, the landscape of accountability, ownership, and profit-sharing could shift considerably.

Today, most intellectual property rights reside with institutions rather than individual researchers. Should patent laws evolve to recognize AI systems or versions thereof as inventors, the implications for how discoveries are commercialized would be profound. It could redefine who holds rights to benefits derived from AI-generated research.

Navigating the Cultural Shift

The existing culture in scientific communities encourages competition for credit among human scientists—believed to be a crucial element in fostering innovation. However, as AI begins to take a more prominent role, this culture will have to adapt. The once clear delineation of credit may lead to new structures that account for AI's integral role in discovery making.

Questions about the future of credit become increasingly pertinent—will it serve solely as an incentive for human researchers, or will it shift to accommodate the complexities introduced by AI? Moreover, discussions surrounding AI as a moral agent further complicate whether these entities could or should receive credit for their contributions.

Ultimately, the issues surrounding AI recognition in scientific discovery are intricate and will likely emerge differently across various sectors: academic institutions, journals, funding agencies, and prize committees. The existing credit framework was constructed for a time when human researchers were the sole agents of discovery. As AI increasingly plays a pivotal role, it's paramount to engage in essential dialogues about how scientific credit will adapt to meet new realities.

Jeffrey S. Flier is a Harvard University distinguished service professor and the former dean of Harvard Medical School.